desloratadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H1 receptor antagonists, tricyclic compounds	814	100643-71-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: SCH-34117 SCH 34117 desloratadine azomyr delopedil descarboethoxyloratadine descarboethoxyloratidine neoclarityn	major metabolite of loratadine Molecular weight: 310.83 Formula: C19H19ClN2 CLOGP: 3.83 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 24.92 ALOGS: -4.90 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

SCH-34117
SCH 34117
desloratadine
azomyr
delopedil
descarboethoxyloratadine
descarboethoxyloratidine
neoclarityn

major metabolite of loratadine

Molecular weight: 310.83
Formula: C19H19ClN2
CLOGP: 3.83
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 24.92
ALOGS: -4.90
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.23 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 2001	FDA	MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	157.48	12.36	114	15788	41339	56234826
Urticaria	125.37	12.36	178	15724	144498	56131667
Rheumatoid arthritis	74.58	12.36	10	15892	382594	55893571
Pruritus	60.00	12.36	211	15691	316412	55959753
Drug reaction with eosinophilia and systemic symptoms	57.81	12.36	56	15846	30248	56245917
Allergy test positive	53.25	12.36	14	15888	396	56275769
Erythema	50.68	12.36	126	15776	155813	56120352
Nasal ulcer	48.72	12.36	19	15883	1943	56274222
Hyponatraemia	47.20	12.36	95	15807	102044	56174121
Toxic skin eruption	46.17	12.36	33	15869	11706	56264459
Endocrine ophthalmopathy	45.73	12.36	13	15889	495	56275670
Hallucination, auditory	44.42	12.36	32	15870	11492	56264673
Dermatitis bullous	43.61	12.36	27	15875	7546	56268619
Intentional self-injury	41.79	12.36	43	15859	24949	56251216
Drug intolerance	39.18	12.36	13	15889	264805	56011360
Haemangioma congenital	38.29	12.36	11	15891	435	56275730
Terminal dribbling	36.79	12.36	6	15896	11	56276154
Intentional overdose	35.90	12.36	67	15835	68050	56208115
Paranoia	35.06	12.36	27	15875	10717	56265448
Toxic shock syndrome	34.62	12.36	11	15891	615	56275550
Systemic lupus erythematosus	32.11	12.36	6	15896	180072	56096093
Eczema	31.65	12.36	38	15864	26115	56250050
Wound	28.54	12.36	3	15899	138801	56137364
Cerebral thrombosis	27.88	12.36	12	15890	1578	56274587
Face oedema	27.74	12.36	30	15872	18422	56257743
Completed suicide	27.24	12.36	3	15899	133830	56142335
Blood immunoglobulin E increased	26.08	12.36	14	15888	2995	56273170
Cholestasis	26.07	12.36	35	15867	26878	56249287
Victim of chemical submission	25.96	12.36	8	15894	404	56275761
Drug ineffective	25.54	12.36	154	15748	918835	55357330
Type IV hypersensitivity reaction	25.21	12.36	13	15889	2563	56273602
Eyelid disorder	25.10	12.36	11	15891	1510	56274655
Death	25.09	12.36	36	15866	341390	55934775
Aggression	25.05	12.36	31	15871	21975	56254190
Skin dystrophy	24.89	12.36	5	15897	40	56276125
Tooth injury	24.80	12.36	10	15892	1116	56275049
Oxalosis	24.67	12.36	5	15897	42	56276123
Somnolence	24.34	12.36	101	15801	163312	56112853
Therapeutic product effect decreased	23.88	12.36	9	15893	169443	56106722
Gestational hypertension	23.65	12.36	12	15890	2287	56273878
Haemorrhagic erosive gastritis	23.60	12.36	7	15895	310	56275855
Mean cell haemoglobin increased	23.17	12.36	12	15890	2388	56273777
Hepatic cytolysis	22.40	12.36	21	15881	10885	56265280
Acute kidney injury	22.35	12.36	130	15772	240633	56035532
Burn oral cavity	22.21	12.36	5	15897	72	56276093
Hyperkalaemia	21.93	12.36	46	15856	50819	56225346
Joint swelling	20.84	12.36	31	15871	289769	55986396
Urticaria thermal	20.18	12.36	6	15896	268	56275897
Swelling of eyelid	19.97	12.36	11	15891	2474	56273691
Tongue oedema	19.91	12.36	13	15889	3979	56272186
Pain	19.50	12.36	109	15793	663075	55613090
Dermatitis exfoliative generalised	19.20	12.36	12	15890	3408	56272757
Hepatocellular injury	19.14	12.36	30	15872	26484	56249681
Arrhythmia	19.09	12.36	35	15867	35048	56241117
Contraindicated product administered	18.84	12.36	15	15887	186271	56089894
Hyperoxaluria	18.25	12.36	5	15897	166	56275999
Inflammatory bowel disease	18.14	12.36	12	15890	3756	56272409
Abortion	18.12	12.36	10	15892	2259	56273906
Nightmare	18.03	12.36	23	15879	16803	56259362
Guttate psoriasis	17.98	12.36	6	15896	392	56275773
Synovitis	17.59	12.36	12	15890	161293	56114872
Psychotic disorder	17.48	12.36	27	15875	23531	56252634
HLA-B*27 positive	17.23	12.36	5	15897	205	56275960
Rash maculo-papular	17.22	12.36	30	15872	28877	56247288
Swelling	16.89	12.36	26	15876	239745	56036420
Photosensitivity reaction	16.85	12.36	20	15882	13573	56262592
Drug dose titration not performed	16.61	12.36	6	15896	496	56275669
Rash erythematous	16.43	12.36	34	15868	37187	56238978
Eosinophilia	16.30	12.36	24	15878	20053	56256112
Urine oxalate increased	16.25	12.36	5	15897	251	56275914
Arteriospasm coronary	16.08	12.36	11	15891	3636	56272529
Keratopathy	15.94	12.36	6	15896	557	56275608
Upper respiratory tract infection bacterial	15.72	12.36	4	15898	99	56276066
Treatment failure	15.68	12.36	15	15887	170377	56105788
Patent ductus arteriosus	15.29	12.36	11	15891	3940	56272225
Subretinal haematoma	15.28	12.36	3	15899	21	56276144
Amnestic disorder	15.05	12.36	5	15897	322	56275843
Hypersensitivity pneumonitis	14.83	12.36	9	15893	2428	56273737
Intraocular haematoma	14.62	12.36	3	15899	27	56276138
Metabolic acidosis	14.51	12.36	34	15868	40420	56235745
Nasal pruritus	14.43	12.36	5	15897	366	56275799
Lip oedema	14.19	12.36	10	15892	3468	56272697
Myalgia	14.04	12.36	74	15828	131951	56144214
Linear IgA disease	14.04	12.36	7	15895	1286	56274879
Pharyngeal oedema	13.98	12.36	18	15884	13267	56262898
Infection	13.82	12.36	22	15880	200184	56075981
Alopecia	13.81	12.36	40	15862	293418	55982747
Feeling hot	13.79	12.36	34	15868	41753	56234412
Food intolerance	13.69	12.36	9	15893	2788	56273377
Vitamin D deficiency	13.62	12.36	17	15885	12153	56264012
Onycholysis	13.59	12.36	7	15895	1377	56274788
Systolic hypertension	13.57	12.36	5	15897	438	56275727
Anaphylactic shock	13.52	12.36	23	15879	21717	56254448
Pancoast's syndrome	13.21	12.36	3	15899	45	56276120
Eyelid erosion	13.09	12.36	3	15899	47	56276118
Fixed eruption	12.96	12.36	6	15896	937	56275228
White blood cell count decreased	12.92	12.36	10	15892	125980	56150185
Therapeutic product effect incomplete	12.79	12.36	7	15895	106024	56170141
Vertigo	12.63	12.36	39	15863	54533	56221632
Disease progression	12.61	12.36	7	15895	105166	56170999
Dyslipidaemia	12.60	12.36	12	15890	6341	56269824
Asthma	12.54	12.36	64	15838	112706	56163459
Hepatic lesion	12.39	12.36	10	15892	4245	56271920

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pruritus	57.09	14.56	108	7854	125059	31564323
Eosinophilia	56.96	14.56	47	7915	23206	31666176
Toxic skin eruption	51.47	14.56	32	7930	10148	31679234
Rash maculo-papular	50.86	14.56	46	7916	25673	31663709
Dermatitis bullous	48.61	14.56	26	7936	6219	31683163
Death	43.82	14.56	18	7944	360551	31328831
Hepatic haematoma	40.90	14.56	11	7951	384	31688998
Xerosis	37.88	14.56	11	7951	510	31688872
Urticaria	37.18	14.56	58	7904	57459	31631923
Hyperkaliuria	36.75	14.56	8	7954	111	31689271
Intentional overdose	35.91	14.56	48	7914	41341	31648041
Eczema	35.33	14.56	30	7932	15387	31673995
Corneal abscess	35.18	14.56	6	7956	19	31689363
Electrocardiogram QT prolonged	31.35	14.56	43	7919	37944	31651438
Rash pustular	28.72	14.56	17	7945	4932	31684450
Acute generalised exanthematous pustulosis	28.06	14.56	18	7944	6022	31683360
Oral dysaesthesia	27.32	14.56	6	7956	87	31689295
Miosis	26.75	14.56	20	7942	8550	31680832
Angioedema	26.16	14.56	37	7925	33581	31655801
Blood immunoglobulin E decreased	25.15	14.56	5	7957	43	31689339
Purpura	24.72	14.56	20	7942	9590	31679792
Keratitis	24.47	14.56	10	7952	1301	31688081
Arrhythmia	23.69	14.56	35	7927	33042	31656340
Prurigo	23.67	14.56	8	7954	612	31688770
Suicide attempt	23.28	14.56	37	7925	37211	31652171
Oedema genital	22.97	14.56	7	7955	384	31688998
Bulbar palsy	21.69	14.56	6	7956	233	31689149
Eyelid ptosis congenital	21.65	14.56	5	7957	92	31689290
Cholangiocarcinoma	21.25	14.56	9	7953	1280	31688102
Disease prodromal stage	21.24	14.56	4	7958	25	31689357
Type III immune complex mediated reaction	20.40	14.56	6	7956	291	31689091
Dermatitis exfoliative	19.93	14.56	15	7947	6477	31682905
Pemphigoid	18.75	14.56	16	7946	8255	31681127
Wrong product administered	18.72	14.56	13	7949	4955	31684427
Rhabdomyolysis	18.69	14.56	46	7916	63535	31625847
Dermatitis psoriasiform	18.54	14.56	8	7954	1192	31688190
Asthma	18.41	14.56	36	7926	42575	31646807
Myoglobin blood increased	18.40	14.56	10	7952	2467	31686915
Retinopathy	18.14	14.56	9	7953	1842	31687540
Spermatic cord disorder	17.71	14.56	3	7959	9	31689373
Hyperlipasaemia	17.28	14.56	6	7956	498	31688884
Hypertrophic cardiomyopathy	17.21	14.56	7	7955	900	31688482
Rhinitis allergic	17.08	14.56	10	7952	2844	31686538
Rash erythematous	16.28	14.56	24	7938	22603	31666779
Purulent pericarditis	15.90	14.56	3	7959	19	31689363
Vasoplegia syndrome	15.82	14.56	8	7954	1705	31687677
Coma	15.68	14.56	33	7929	41117	31648265
Intentional self-injury	15.65	14.56	18	7944	13297	31676085
Cerebral venous thrombosis	15.59	14.56	6	7956	667	31688715
Wrong patient received product	15.40	14.56	9	7953	2550	31686832
Ischaemic cerebral infarction	15.39	14.56	7	7955	1180	31688202
Neonatal pneumonia	15.12	14.56	4	7958	131	31689251
Hepatic cytolysis	15.09	14.56	16	7946	10807	31678575
Vascular cognitive impairment	14.59	14.56	3	7959	31	31689351

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	149.69	12.23	208	20153	162841	70745242
Angioedema	140.53	12.23	131	20230	66479	70841604
Pruritus	112.66	12.23	282	20079	345278	70562805
Toxic skin eruption	83.84	12.23	59	20302	20103	70887980
Dermatitis bullous	81.81	12.23	49	20312	12708	70895375
Eosinophilia	67.64	12.23	70	20291	40249	70867834
Eczema	64.66	12.23	63	20298	33718	70874365
Rash maculo-papular	59.54	12.23	73	20288	50472	70857611
Rheumatoid arthritis	57.12	12.23	8	20353	291797	70616286
Allergy test positive	56.59	12.23	15	20346	431	70907652
Death	54.80	12.23	40	20321	510021	70398062
Nasal ulcer	46.31	12.23	18	20343	1795	70906288
Hallucination, auditory	44.41	12.23	39	20322	18289	70889794
Endocrine ophthalmopathy	44.29	12.23	13	20348	546	70907537
Erythema	43.46	12.23	141	20220	199422	70708661
Drug reaction with eosinophilia and systemic symptoms	41.60	12.23	66	20295	57947	70850136
Completed suicide	38.46	12.23	9	20352	227126	70680957
Arrhythmia	37.70	12.23	62	20299	56081	70852002
Hepatic cytolysis	37.11	12.23	36	20325	19156	70888927
Intentional overdose	36.95	12.23	85	20276	98350	70809733
Terminal dribbling	36.69	12.23	6	20355	11	70908072
Face oedema	35.10	12.23	40	20321	25599	70882484
Electrocardiogram QT prolonged	34.58	12.23	75	20286	83442	70824641
Rash erythematous	34.57	12.23	57	20304	51661	70856422
Drug intolerance	34.35	12.23	11	20350	225676	70682407
Somnolence	33.09	12.23	136	20225	215470	70692613
Hyponatraemia	32.95	12.23	111	20250	159976	70748107
Cholestasis	32.32	12.23	53	20308	47819	70860264
Hyperkaliuria	32.09	12.23	8	20353	179	70907904
Aggression	31.85	12.23	53	20308	48393	70859690
Hepatic haematoma	31.42	12.23	11	20350	817	70907266
Blood immunoglobulin E increased	29.84	12.23	18	20343	4726	70903357
Toxic shock syndrome	29.20	12.23	11	20350	1007	70907076
Corneal abscess	28.85	12.23	6	20355	57	70908026
Acute generalised exanthematous pustulosis	28.12	12.23	28	20333	15369	70892714
Cerebral thrombosis	26.54	12.23	13	20348	2263	70905820
Gestational hypertension	26.26	12.23	12	20349	1788	70906295
Nightmare	26.08	12.23	32	20329	22124	70885959
Victim of chemical submission	25.53	12.23	8	20353	420	70907663
Xerosis	25.53	12.23	10	20351	1018	70907065
Paranoia	25.42	12.23	28	20333	17260	70890823
Oedema genital	24.63	12.23	8	20353	472	70907611
Hepatocellular injury	24.58	12.23	46	20315	46045	70862038
Eyelid disorder	24.11	12.23	11	20350	1633	70906450
Type IV hypersensitivity reaction	23.76	12.23	14	20347	3521	70904562
Skin dystrophy	23.63	12.23	5	20356	52	70908031
Abortion	23.39	12.23	10	20351	1272	70906811
Prurigo	23.31	12.23	10	20351	1283	70906800
Acute kidney injury	22.81	12.23	222	20139	474402	70433681
Burn oral cavity	22.53	12.23	5	20356	66	70908017
Oral dysaesthesia	22.45	12.23	6	20355	178	70907905
Vertigo	21.23	12.23	52	20309	62591	70845492
Oxalosis	20.45	12.23	5	20356	103	70907980
HLA-B*27 positive	20.40	12.23	5	20356	104	70907979
Platelet count decreased	20.39	12.23	13	20348	178209	70729874
Swelling of eyelid	20.36	12.23	12	20349	3020	70905063
Bulbar palsy	20.35	12.23	6	20355	256	70907827
Hyperkalaemia	20.25	12.23	72	20289	106519	70801564
Tooth injury	20.12	12.23	10	20351	1795	70906288
Urticaria thermal	20.07	12.23	6	20355	269	70907814
White blood cell count decreased	20.03	12.23	12	20349	170129	70737954
Purpura	19.62	12.23	25	20336	17950	70890133
Haemorrhagic erosive gastritis	19.58	12.23	7	20354	553	70907530
Miosis	19.30	12.23	22	20339	14079	70894004
Rhinitis allergic	19.04	12.23	18	20343	9277	70898806
Suicide attempt	18.95	12.23	58	20303	79452	70828631
Type III immune complex mediated reaction	18.71	12.23	7	20354	629	70907454
Tongue oedema	18.63	12.23	15	20346	6244	70901839
Rhabdomyolysis	18.46	12.23	65	20296	95695	70812388
Photosensitivity reaction	18.18	12.23	25	20336	19315	70888768
Therapeutic product effect incomplete	17.95	12.23	6	20355	119876	70788207
Guttate psoriasis	17.20	12.23	6	20355	441	70907642
Disease progression	17.15	12.23	12	20349	156660	70751423
Dermatitis exfoliative	17.11	12.23	18	20343	10533	70897550
Cerebral venous thrombosis	17.01	12.23	10	20351	2505	70905578
Inflammatory bowel disease	16.98	12.23	13	20348	5033	70903050
Therapeutic product effect decreased	16.96	12.23	10	20351	143008	70765075
Serum amyloid A protein increased	16.58	12.23	5	20356	231	70907852
Coma	16.56	12.23	61	20300	91783	70816300
Wound	16.53	12.23	4	20357	98728	70809355
Urine oxalate increased	16.43	12.23	5	20356	238	70907845
Dermatitis exfoliative generalised	16.25	12.23	14	20347	6400	70901683
Intentional self-injury	16.14	12.23	31	20330	31619	70876464
Mean cell haemoglobin increased	16.13	12.23	11	20350	3562	70904521
Pancreatitis acute	15.81	12.23	38	20323	45186	70862897
Rash pustular	15.69	12.23	17	20344	10291	70897792
Keratitis	15.63	12.23	11	20350	3746	70904337
Sepsis	15.60	12.23	29	20332	244516	70663567
Hypersensitivity vasculitis	15.50	12.23	14	20347	6808	70901275
Hyperlipasaemia	15.26	12.23	7	20354	1053	70907030
Myoglobin blood increased	15.24	12.23	10	20351	3037	70905046
Hyperoxaluria	15.14	12.23	5	20356	311	70907772
Feeling hot	15.02	12.23	39	20322	48631	70859452
Arteriospasm coronary	14.96	12.23	13	20348	6011	70902072
Cholangiocarcinoma	14.81	12.23	9	20352	2395	70905688
Asthma	14.59	12.23	71	20290	120722	70787361
Upper respiratory tract infection bacterial	14.56	12.23	4	20357	132	70907951
Onycholysis	14.42	12.23	8	20353	1795	70906288
Altered state of consciousness	14.39	12.23	34	20327	39988	70868095
Anaphylactic shock	14.39	12.23	30	20331	32460	70875623
Drug dose titration not performed	14.11	12.23	6	20355	753	70907330
Vascular cognitive impairment	14.02	12.23	3	20358	33	70908050
Retinopathy	13.97	12.23	10	20351	3496	70904587
Lip oedema	13.76	12.23	12	20349	5571	70902512
Pain	13.32	12.23	116	20245	628700	70279383
Drug level increased	13.13	12.23	31	20330	36438	70871645
Pemphigoid	12.99	12.23	18	20343	14004	70894079
Dyspepsia	12.72	12.23	55	20306	89022	70819061
Arthrodesis	12.71	12.23	8	20353	2265	70905818
Keratopathy	12.70	12.23	6	20355	964	70907119
Urticaria chronic	12.66	12.23	5	20356	520	70907563
Coronavirus infection	12.60	12.23	12	20349	6240	70901843
Dermatitis psoriasiform	12.58	12.23	8	20353	2305	70905778
Disease prodromal stage	12.40	12.23	3	20358	59	70908024
Alopecia areata	12.38	12.23	7	20354	1629	70906454
Abortion spontaneous	12.37	12.23	25	20336	26454	70881629
Febrile neutropenia	12.36	12.23	25	20336	204293	70703790
Nutritional condition abnormal	12.36	12.23	6	20355	1024	70907059
Acute haemorrhagic oedema of infancy	12.35	12.23	3	20358	60	70908023

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AX27	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Other antihistamines for systemic use
FDA MoA	N0000000190	Histamine H1 Receptor Antagonists
FDA EPC	N0000175587	Histamine-1 Receptor Antagonist
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D039563	Histamine H1 Antagonists, Non-Sedating
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:50857	anti-allergic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Allergic urticaria	indication	40178009	DOID:10612
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Sneezing	indication	76067001
Common cold	indication	82272006	DOID:10459
Chronic idiopathic urticaria	indication	302162004
Seasonal allergic rhinitis	indication	367498001
Allergic conjunctivitis	indication	473460002	DOID:11204
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.92	Basic
pKa2	2.48	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.40	WOMBAT-PK	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.91	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.96	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.03	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.55	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.80	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.00	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.01	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.19	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.97	DRUG MATRIX
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		IC50	4.80	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.74	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.60	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.49	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.70	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.30	WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.51	DRUG MATRIX
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.37	WOMBAT-PK
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.70	DRUG MATRIX

External reference:

ID	Source
4021292	VUID
N0000148729	NUI
D03693	KEGG_DRUG
275635	RXNORM
4021292	VANDF
C0908935	UMLSCUI
CHEBI:291342	CHEBI
CHEMBL1172	ChEMBL_ID
DB00967	DRUGBANK_ID
C121345	MESH_SUPPLEMENTAL_RECORD_UI
124087	PUBCHEM_CID
7157	IUPHAR_LIGAND_ID
7817	INN_ID
FVF865388R	UNII
16243	MMSL
42606	MMSL
51632	MMSL
83662	MMSL
d04785	MMSL
009081	NDDF
134506008	SNOMEDCT_US
396015008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	21695-815	TABLET, FILM COATED	5 mg	ORAL	NDA	23 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-240	TABLET	5 mg	ORAL	ANDA	26 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0765	TABLET, FILM COATED	5 mg	ORAL	NDA	29 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3975	TABLET	5 mg	ORAL	ANDA	30 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4794	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4624	TABLET, FILM COATED	5 mg	ORAL	NDA	12 sections
Clarinex-D 12 Hour	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5708	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	55111-360	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	26 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	55111-551	TABLET, ORALLY DISINTEGRATING	2.50 mg	ORAL	ANDA	26 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	62250-619	TABLET	5 mg	ORAL	ANDA	25 sections
Desloratadine	Human Prescription Drug Label	1	62756-523	TABLET, FILM COATED	5 mg	ORAL	ANDA	28 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	68180-153	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	69543-107	TABLET	5 mg	ORAL	ANDA	29 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1000	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-119	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-119	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-119	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections
CLARINEX-D 12 HOUR	HUMAN PRESCRIPTION DRUG LABEL	2	78206-120	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
CLARINEX-D 12 HOUR	HUMAN PRESCRIPTION DRUG LABEL	2	78206-120	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
CLARINEX-D 12 HOUR	HUMAN PRESCRIPTION DRUG LABEL	2	78206-120	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-188	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections